Marco Meglio

Takeda reveals promising phase 3 results for oveporexton, a potential breakthrough treatment for narcolepsy type 1, targeting excessive daytime sleepiness.

INmune Bio's XPro shows promise as a treatment for patients with Alzheimer disease, revealing cognitive benefits despite mixed phase 2 trial results.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the Alzheimer's Association International Conference.

A recent study reveals a decline in multiple sclerosis progression rates, highlighting the impact of improved treatments and the need for ongoing innovation in care.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Joyce Lee-Iannotti, MD, PhD. [LISTEN TIME: 17 minutes]

A recent study confirmed ambroxol's safety in Parkinson disease dementia, showing stabilization of neuropsychiatric symptoms but no cognitive improvement.

The updated donanemab dosing schedule is aimed at reducing ARIA risk while maintaining efficacy in early Alzheimer treatment to enhance patient safety.

The chief medical and scientific officer at Harmony Biosciences discussed the pharmacologic rationale and preclinical development of BP1.15205, a novel orexin receptor 2 agonist for hypersomnolence.

A recent trial reveals that a flat head position before thrombectomy significantly reduces the risk of neurological deterioration in stroke patients.

Eptinezumab showed significant efficacy in reducing chronic migraine days in Asian patients, potentially addressing a critical unmet need for effective treatments.

The associate professor of neurology at the Icahn School of Medicine at Mount Sinai detailed how monitoring tools and neuroprotective approaches are evolving for iRBD as research intensifies on its link to Parkinsonian syndromes. [WATCH TIME: 4 minutes]

The professor of neurology at the Miami Miller School of Medicine discussed how the Cognivue Amyloid Risk Measure (CARM) may help predict amyloid presence and informs diagnosis, trial eligibility, and early treatment pathways.

Denali Therapeutics advances treatment for Hunter syndrome with FDA's priority review of tividenofusp alfa, targeting brain delivery and improved patient outcomes.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on stroke triage.

Laren Becker, MD, PhD, a physician-scientist at Stanford University, discussed how gastrointestinal dysfunction and peripheral dopaminergic activity impact Parkinson disease treatment and progression.

Continuous subcutaneous apomorphine infusion significantly reduces OFF episodes and enhances ON time in Parkinson's disease patients, improving overall health status.

Research reveals that delayed-release amantadine significantly reduces Parkinson disease symptoms and medication use, offering patients improved quality of life.

The associate professor of neurology at the Icahn School of Medicine at Mount Sinai explained how his team validated an iRBD actigraphy classifier across new devices and datasets to enhance early, scalable screening for neurodegenerative disease. [WATCH TIME: 5 minutes]

New findings reveal deramiocel's promising long-term benefits for boys with Duchenne muscular dystrophy cardiomyopathy, enhancing cardiac function and muscle performance.

New phase 1 data revealed salanersen's promise to slow neurodegeneration in spinal muscular atrophy, potentially paving the way for future phase 3 trials.

Edgewise Therapeutics reveals promising results for sevasemten, potentially the first approved treatment for Becker muscular dystrophy, enhancing patient outcomes.

Overviewing the major clinical trial readouts in neurology from the first half of 2025, with data that could reshape patient care.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ATMRD Congress.

A recent analysis reveals significant links between sleep, quality of life, and daily activities in patients with Parkinson disease, highlighting benefits of Vyalev treatment.

Continuous subcutaneous apomorphine infusion enhances confidence and reduces treatment burden for Parkinson's patients, improving daily activity engagement.

UCB has recently announced promising phase 3 trial results of fenfluramine, a potential new treatment to enhance seizure control for CDKL5 deficiency disorder.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Joseph Sullivan, MD. [LISTEN TIME: 14 minutes]

New findings reveal eptinezumab significantly reduces migraine days and medication use in chronic migraine patients, offering hope for effective treatment.

New data reveals vidofludimus calcium effectively maintains low disability progression in relapsing-remitting multiple sclerosis over 144 weeks, enhancing patient quality of life.

Grace Therapeutics submits NDA for GTx-104, a promising IV treatment for aSAH, aiming to revolutionize patient care and improve outcomes.